1. Home
  2. ERO vs HRMY Comparison

ERO vs HRMY Comparison

Compare ERO & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ero Copper Corp.

ERO

Ero Copper Corp.

HOLD

Current Price

$25.68

Market Cap

2.7B

Sector

N/A

ML Signal

HOLD

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

HOLD

Current Price

$36.58

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ERO
HRMY
Founded
2016
2017
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
2.2B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
ERO
HRMY
Price
$25.68
$36.58
Analyst Decision
Buy
Buy
Analyst Count
2
9
Target Price
$36.50
$44.11
AVG Volume (30 Days)
1.2M
768.4K
Earning Date
05-04-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.97
EPS
N/A
0.55
Revenue
N/A
$868,453,000.00
Revenue This Year
$51.94
$19.75
Revenue Next Year
$2.43
$12.88
P/E Ratio
$22.61
$69.47
Revenue Growth
N/A
21.51
52 Week Low
$12.79
$25.52
52 Week High
$39.80
$40.87

Technical Indicators

Market Signals
Indicator
ERO
HRMY
Relative Strength Index (RSI) 44.84 58.67
Support Level $25.42 $35.05
Resistance Level $26.77 $39.12
Average True Range (ATR) 1.24 1.23
MACD -0.23 0.13
Stochastic Oscillator 36.03 60.10

Price Performance

Historical Comparison
ERO
HRMY

About ERO Ero Copper Corp.

Ero Copper Corp is a high-margin, high-growth copper producer with operations in Brazil. Its primary asset is its 99.6% ownership interest in Mineracao Caraiba S.A., held indirectly through its wholly-owned subsidiary. The company also owns a 97.6% ownership interest in NX Gold S.A. indirectly through its wholly-owned subsidiary. Its reporting segments include its three operating mines in Brazil, the Caraiba Operations, the Tucuma Operation, and the Xavantina Operations, and its corporate head office in Canada.

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Share on Social Networks: